Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Opioid receptor antagonists reduce motivated wheel-running behavior in mice

View through CrossRef
We hypothesized that opioid receptor antagonists would inhibit motivated behavior produced by a natural reward. To evaluate motivated responses to a natural reward, mice were given access to running wheels for 71.5 h in a multi-configuration testing apparatus. In addition to a running wheel activity, locomotor activity (outside of the wheel), food and water intake, and access to a food container were measured in the apparatus. Mice were also tested separately for novel-object exploration to investigate whether naloxone affects behavior unrelated to natural reward. In untreated mice wheel running increased from day 1 to day 3. The selective µ-opioid receptor antagonist β-funaltrexamine (β-FNA) (5 mg/kg) slightly decreased wheel running, but did not affect the increase in wheel running from day 1 to day 3. The non-selective opioid receptor antagonist naloxone produced a greater reduction in wheel running than β-FNA and eliminated the increase in wheel running that occurred over time in the other groups. Analysis of food access, locomotor behavior, and behavior in the novel-object test suggested that the reduction in wheel running was selective for this highly reinforcing behavior. These results indicate that opioid receptor antagonism reduces responses to the natural rewarding effects of wheel running and that these effects involve multiple opioid receptors since the non-selective opioid receptor antagonist had greater effects than the selective µ-opioid receptor antagonist. It is possible that at the doses employed, other receptor systems than opioid receptors might be involved, at least in part, in the effect of naloxone and β-FNA.
Title: Opioid receptor antagonists reduce motivated wheel-running behavior in mice
Description:
We hypothesized that opioid receptor antagonists would inhibit motivated behavior produced by a natural reward.
To evaluate motivated responses to a natural reward, mice were given access to running wheels for 71.
5 h in a multi-configuration testing apparatus.
In addition to a running wheel activity, locomotor activity (outside of the wheel), food and water intake, and access to a food container were measured in the apparatus.
Mice were also tested separately for novel-object exploration to investigate whether naloxone affects behavior unrelated to natural reward.
In untreated mice wheel running increased from day 1 to day 3.
The selective µ-opioid receptor antagonist β-funaltrexamine (β-FNA) (5 mg/kg) slightly decreased wheel running, but did not affect the increase in wheel running from day 1 to day 3.
The non-selective opioid receptor antagonist naloxone produced a greater reduction in wheel running than β-FNA and eliminated the increase in wheel running that occurred over time in the other groups.
Analysis of food access, locomotor behavior, and behavior in the novel-object test suggested that the reduction in wheel running was selective for this highly reinforcing behavior.
These results indicate that opioid receptor antagonism reduces responses to the natural rewarding effects of wheel running and that these effects involve multiple opioid receptors since the non-selective opioid receptor antagonist had greater effects than the selective µ-opioid receptor antagonist.
It is possible that at the doses employed, other receptor systems than opioid receptors might be involved, at least in part, in the effect of naloxone and β-FNA.

Related Results

GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
Objectives Low density lipoprotein receptor defect mice model by transgenetic technology was used to detect atherosclerosis by Ultrasound Biology (UBM). And evalu...
Implementation of a Quality Improvement Initiative to Decrease Opioid Prescribing After Cesarean Delivery
Implementation of a Quality Improvement Initiative to Decrease Opioid Prescribing After Cesarean Delivery
OBJECTIVE: To assess whether a multiphase, departmental quality improvement effort decreases opioid prescribing and increases multimodal analgesic use after cesarean de...
Impact of continuous infusions of opioids on discharge opioid prescriptions
Impact of continuous infusions of opioids on discharge opioid prescriptions
Introduction: The 2018 Pain, Agitation/Sedation, Delirium, Immobility, and Sleep guidelines from the Society of Critical Care Medicine recommend opioids as a first-line treatment o...
Exploring the impact of the opioid epidemic in Black and Hispanic communities in the United States
Exploring the impact of the opioid epidemic in Black and Hispanic communities in the United States
Context: In recent years, due to an alarming increase in the number of opioid-related overdose fatalities for White, Non-Hispanics in rural and suburban communities across the Unit...
Abstract 4360: Opioid, non-opioid, and non-pharmacological pain management in patients with a history of cancer
Abstract 4360: Opioid, non-opioid, and non-pharmacological pain management in patients with a history of cancer
Abstract Background Pain is highly prevalent among individuals with cancer. Consequently, adequate and equitable pain management are hallmarks of quality cancer care...
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Abstract Background: The management of pain in adults with sickle cell disease (SCD) is complex, with the intermingling of both acute vaso-occlusive events and chron...

Back to Top